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Merging alcohol giants threaten global health
Alcohol has comparable health risks to tobacco but none of its pariah status
Jeff Collin professor of global health policy, Sarah E Hill senior lecturer, Katherine E Smith reader
Global Public Health Unit, School of Social and Political Science, University of Edinburgh, Edinburgh EH8 9LD, UK
The world’s two largest beer manufacturers, Anheuser-Busch
InBev (AB InBev) and SABMiller, have agreed in principle to
merge. AB InBev, the Belgium based producer of global brands
such as Budweiser, Corona, and Stella Artois will acquire
London based SABMiller, brewer of Peroni,Miller, andGrolsch.
At £70bn (€100bn; $106bn) this would be the third largest deal
in corporate history, establishing a dominant position in the
global beer market.1 Its completion depends on navigating the
regulatory demands of competition policy in multiple
jurisdictions. Yet the real importance of the deal is what it
symbolises for the future of the global alcohol industry. Here
we focus on its implications for the growing epidemic of alcohol
related harm across low and middle income countries.
The health interest of this business story lies partly in the sheer
scale of themerger. The new companywill produce an estimated
one third of all beer sold worldwide and will be market leader
in 24 of the world’s 30 largest beer markets.2 Importantly for
global health, the merger is driven by prospects for expansion
in developing countries. In promoting the deal to investors, AB
InBev highlighted the complementary geographical strengths
of the two businesses in “key emerging regions with strong
growth prospects, including Africa, Asia and Central and South
America,” with a particular emphasis on Africa as “a critical
driver of growth for the combined company.”3 This ambition
mirrors industry analysts’ identification of Africa as the “final
frontier for beer,”4 projected to be the world’s fastest growing
region for alcoholic drinks over 2013-18.
SABMiller, which originated in South Africa, is the established
industry leader in the region and so is well placed to exploit
growth across sub-Saharan Africa. The health implications of
this forecast are disturbing: market growth on this scale is
predicated on “exploiting Africa’s low per capita consumption
of beer,” targeting low income consumers to drive increased
sales.4
This expansive trajectory echoes that of transnational tobacco
companies, with which the alcohol industry shares strategic
similarities and has close corporate links as well as comparable
health effects.5 6 SABMiller is 27% owned by the cigarette giant
Altria (responsible for large brands, includingMarlboro), which
supplies three directors to the SABMiller board, and its new
chair is a former chair of British American Tobacco.7 Thus far,
however, global health and development agencies have engaged
with these two industries on starkly contrasting terms.
Tobacco companies are regulated as transnational vectors of
disease on the basis of a fundamental conflict of interest with
public health; voluntary approaches have been rejected as
inadequate and inappropriate, and there are coordinated
regulatory strategies centred on the WHO Framework
Convention on Tobacco Control.6 Conversely, SABMiller, for
example, participated in the UN high level meeting on
non-communicable diseases that produced a declaration
emphasising scope for voluntary measures and partnerships
with producers in reducing alcohol related harm.8 SABMiller
was also represented at a consultation on the process of
reforming WHO’s engagement with non-state actors,9 and
company led initiatives have even received development funding
from the UK’s Department for International Development and
the Global Fund.8 10 SABMiller’s deeply embedded position in
health and development networks is epitomised by the recent
addition to its board of directors of TrevorManuel, longstanding
finance minister in South Africa and former chair of the World
Bank’s development committee and the board of governors of
the International Monetary Fund.7
The proposed merger with AB InBev represents a major threat
to global health, to which researchers, funders, and regulators
must respond more effectively. The new sustainable
development goals provide opportunities here, through the focus
(in goal 3) on reducing mortality from non-communicable
diseases, including through strengthened prevention and
treatment of harmful alcohol use. Importantly, the goal also
includes a commitment to strengthen “the capacity of all
countries, in particular developing countries, for early warning,
risk reduction, and management of national and global health
risks.”11
The global alcohol industry comprises such a risk and should
be regulated accordingly. Although regulation underpins efforts
to control transnational tobacco companies, the global alcohol
industry continues to occupy an ambiguous space in which an
indirect acknowledgment of serious health effects coexists with
the prospect of partnerships and shared objectives. WHO’s
emerging framework for engagement with non-state actors, for
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example, precludes partnership with the tobacco and arms
industries but makes no specific reference to alcohol.12
Public health must therefore do more to ensure that conflict of
interest with alcohol companies is recognised and addressed.
Acknowledging such conflicts in the terms for WHO’s
interactions with non-state actors, and protecting against them
on the same basis as for tobacco, would be an appropriate
starting point.
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